Elm Street Ventures logo

Elm Street Ventures

North America, Connecticut, United States, New Haven

Description

Elm Street Ventures (ESVC) is a specialized venture capital firm headquartered in New Haven, Connecticut, with a distinct investment mandate. Its core strategy revolves around identifying, creating, and funding life sciences and technology companies that are built upon intellectual property originating from Yale University. This unique and deeply integrated relationship with Yale positions ESVC as a critical conduit for translating cutting-edge academic research into commercial enterprises, fostering innovation within the university's robust ecosystem.

The firm primarily deploys seed and early-stage capital, often adopting a highly engaged approach that extends beyond traditional investment. ESVC frequently plays an active role in the initial formation and operational development of its portfolio companies, reflecting a "company creator" model rather than just a passive investor. This hands-on involvement is crucial for guiding nascent ventures through their foundational stages, ensuring that promising technologies are properly structured and resourced for market entry and growth. Their focus remains on ventures with strong proprietary technology and significant market potential, leveraging Yale's extensive research and development capabilities.

Elm Street Ventures has successfully raised multiple funds to support its focused investment thesis. For example, their Elm Street Ventures V fund closed in 2017, securing $35 million in commitments, which followed their Elm Street Ventures IV fund that closed at $25 million in 2011. The firm typically invests initial checks ranging from $500,000 to $3 million in its portfolio companies, demonstrating their commitment to providing substantial early-stage support. Furthermore, ESVC strategically reserves capital for follow-on investments, enabling them to continue backing their companies through subsequent funding rounds as they achieve critical milestones and scale their operations. This long-term commitment underscores their dedication to nurturing the growth and success of Yale-derived innovations.

Investor Profile

Elm Street Ventures has backed more than 28 startups, with 1 new investments in the last 12 months alone. The firm has led 4 rounds, about 14% of its total and boasts 8 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Series Unknown, Seed rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Health Care, Therapeutics.
  • Typical check size: $500K – $3M.

Stage Focus

  • Series A (43%)
  • Series Unknown (21%)
  • Seed (18%)
  • Series B (14%)
  • Series C (4%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Biopharma
  • Medical
  • Pharmaceutical
  • Chemical
  • Renewable Energy
  • Software
  • Oncology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Elm Street Ventures frequently co-invest with?

HBM Healthcare Investments
Europe, Zug, Switzerland, Zug
Co-Investments: 2
Hatteras Venture Partners
North America, North Carolina, United States, Durham
Co-Investments: 2
Canaan Partners
North America, California, United States, Menlo Park
Co-Investments: 3
Alpine Meridian
North America, New York, United States, New York
Co-Investments: 2
Connecticut Innovations
North America, Connecticut, United States, Rocky Hill
Co-Investments: 12
ATDC
North America, Georgia, United States, Atlanta
Co-Investments: 2
Advantage Capital
North America, Louisiana, United States, New Orleans
Co-Investments: 3
OUP (Osage University Partners)
North America, Pennsylvania, United States, Bala Cynwyd
Co-Investments: 4
Cota Capital
North America, California, United States, San Francisco
Co-Investments: 2
New York Angels
North America, New York, United States, New York
Co-Investments: 2

What are some of recent deals done by Elm Street Ventures?

Halda Therapeutics

New Haven, Connecticut, United States

Halda Therapeutics is a research-stage drug discovery company.

BiotechnologyMedicalTherapeutics
Series BAug 12, 2024
Amount Raised: $126,000,000
EvolveImmune Therapeutics

Branford, Connecticut, United States

EvolveImmune Therapeutics develops a modular biotherapeutics platform specialized in immuno-oncology.

BiotechnologyHealth CareMedicalOncologyTherapeutics
Series UnknownNov 16, 2023
Amount Raised: $37,398,371
CellFE

Alameda, California, United States

CellFE is a company developing a microfluidics based device to deliver gene-editing molecules.

BiotechnologyHealth Care
Series ASep 27, 2023
Amount Raised: $22,000,000
P2 Science

Woodbridge, Connecticut, United States

P2 Science develops a bio-refining process for the conversion of biomass such as vegetable oils into high-value specialty chemicals.

BiotechnologyChemicalRenewable Energy
Series UnknownFeb 23, 2023
Allyx Therapeutics

New Haven, Connecticut, United States

Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies to reverse neurodegeneration.

BiotechnologyHealth CareLife ScienceMedical
Series AJun 1, 2021
Amount Raised: $7,581,493
Cybrexa Therapeutics

New Haven, Connecticut, United States

Cybrexa Therapeutics is a cancer therapeutics company developing a new class of small molecule DNA repair.

BiotechnologyPharmaceuticalTherapeutics
Series BMar 10, 2021
Amount Raised: $25,000,000
Artizan Biosciences

New York, New York, United States

Artizan Biosciences focuses on drug discovery and development for diseases involving the human intestinal microbiota.

BiopharmaBiotechnologyHealth CareLife Science
Series AMar 1, 2021
Amount Raised: $18,877,921
P2 Science

Woodbridge, Connecticut, United States

P2 Science develops a bio-refining process for the conversion of biomass such as vegetable oils into high-value specialty chemicals.

BiotechnologyChemicalRenewable Energy
Series CJan 29, 2020
Amount Raised: $12,000,000
CellFE

Alameda, California, United States

CellFE is a company developing a microfluidics based device to deliver gene-editing molecules.

BiotechnologyHealth Care
SeedJan 16, 2020
Amount Raised: $4,800,000
EvolveImmune Therapeutics

Branford, Connecticut, United States

EvolveImmune Therapeutics develops a modular biotherapeutics platform specialized in immuno-oncology.

BiotechnologyHealth CareMedicalOncologyTherapeutics
Series AJan 8, 2020
Amount Raised: $17,549,992